Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underw...
ENGLEWOOD, CO / ACCESSWIRE / December 14, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will present at the LD Micro Virtual Inve...
Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...
Nabriva Therapeutics NBRV -30% after priced $15M public offering.Aytu BioScience (AYTU) -25% on raising 'bought deal' offering to $25M.Immutep (IMMP) -24%.Professional Diversity Network (IPDN) -24%.SELLAS Life Sciences Group SLS -21% after announcing positiv...
Aytu BioScience (AYTU) announces that H.C. Wainwright & Co., the sole underwriter for the offering, has agreed to increase the size of the previous offering and purchase on a firm commitment basis ~4.17M common shares at $6.00/share, for expected gross proceeds of ~$25M. Underwriter's ove...
ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that, due to demand, the underwriter has agreed to increase the size of t...
Aytu BioScience (AYTU) enters into an underwriting agreement with H.C. Wainwright & Co to purchase on a firm commitment basis ~1.67M shares at a price to the public of $6.00 per share, less underwriting discounts and commissions. Underwriters' option for additional 250,000 shares.Off...
ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it has entered into an underwriting agreement with H.C. Wainwright &...
Gainers: Immutep (IMMP) +166%.SELLAS Life Sciences (SLS) +90%.Neos Therapeutics (NEOS) +65%.Greenwich LifeSciences (GLSI) +51%.Aytu BioScience (AYTU) +34%.Veru (VERU) +34%.Silver Spike Acquisition (SSPK) +32%.8x8 (EGHT) +32%.TG Therapeutics (TGTX) +31%.Peabody Energy (BTU) +29%...
Merger accelerates transformation to profitability, with estimated annual ized cost synergies of $15M beginning FY 2022 A ytu a dds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and e...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...